Prognostic importance of previous myocardial infarction in patients receiving thrombolytic therapy for acute infarction

Journal of Thrombosis and Thrombolysis

Volumn 3, Issue 4, 1996, Pages 391-395

  Kornowski, Ran ^a,b   Chetrit, Angela ^a   Barbash, Gabriel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Myocardial infarction; Prognosis; Reinfarction; Thrombolysis

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029843009     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00133083     Document Type: Article

References (29)

1. Muller JE, Rude RE, Braunwald E, et al. and The Millis Study Group. Myocardial infarct extension: Occurrence, outcome, and risk factors in the multicenter investigation of limitation of infarct size. Ann Intern Med 1988;108:1-6.
2. Hoit BD, Gilpin EA, Henning H, Maisel AA, Dittrich H, Carlisle J, Ross J Jr. Myocardial infarction in young patients: An analysis by age subsets. Circulation 1986;74: 712-721.
3. Greenberg H, McMaster P, Dwyer EM Jr, and the Multicenter Post-Infarction Research group. Left ventricular dysfunction after acute myocardial infarction: Results of a prospective multicenter study. J Am Coll Cardiol 1984; 4:867-874.
4. Williams WL, Nair RC, Higginson LAJ, Baird MG, Allan K, Beanlands DS. Comparison of clinical and treadmill variables for the prediction of outcome after myocardial infarction. J Am Coll Cardiol 1984;4:477-486.
5. Madsen EB, Gilpin E, Henning H, et al. Prediction of late mortality after myocardial infarction from variables measured at different times during hospitalization. Am J Cardiol 1984;53:47-54.
6. Nicod P, Gilpin E, Dittrich H, et al. Short and long term clinical outcome after Q wave and non-Q wave myocardial infarction. Circulation 1989;79:528-548.
7. Benhorin J, Moss AJ, Oakes D. Prognostic significance of non-fatal myocardial infarction. J Am Coll Cardiol 1990;15: 253-258.
8. Kornowski R, Goldbourt U, Zion M, Mandelzweig L, Kaplinski E, Levo Y, Behar S. Predictors and long term prognostic significance of recurrent infarction in the year after a first myocardial infarction. Am J Cardiol 1993;72: 883-888.
9. Wilcox RG, Olsson CG, Skene AM, Von der Lippe G, Jensen G, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;2:525-530.
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:1-12.
11. Gruppo Italiano per lo Studio Della Streptochonasi Nell'infarto Myocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:396-401.
12. Simmons ML, Brand M, de Zwaans C, et al. Improved survival after early thrombolysis in acute myocardial infarction. A Randomized Trial by the Interuniversity Cardiology Institute in the Netherlands. Lancet 1985;2:578-582.
13. Wilcox RG, Von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton Jr for the Anglo-Scandinavian Study of Early Thrombolysis. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Lancet 1990;1:1175-1178.
14. Hillis LD, Forman S, Braunwald E, and The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1990; 16:313-315.
15. The International Study Group. In hospital mortality and clinical course of 10,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990;2:71-75.
16. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
17. Van de Werf F, Arnold AER. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 1988; 297:1374-1379.
18. The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). N Engl J Med 1986;314:1465-1471.
19. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317:850-855.
20. Kennedy JW. Expending the use of thrombolytic therapy for acute myocardial infarction. Ann Intern Med 1990;113: 907-908.
21. Muller DWM, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med 1990;113:949-960.
22. Moshkovitz Y, Sclerovsky S, Behar S, Reicher-Reiss H, Kaplinsky E, Golbourt U. Infarct site-related mortality in patients with recurrent myocardial infarction. Am J Med 1993;94:388-394.
23. Gruppo Italiano per lo Studio Della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
24. Bebhorin J, Moss AJ, Oakes D, et al. and the Multicenter Diltiazem Post-infarction Research Group. J Am Coll Cardiol 1990;15:1201-1207.
25. Stone PH, Raabe DS, Jaffe AS, et al. Prognostic significance of location and type of myocardial infarction: Independent adverse outcome associated with anterior location. J Am Coll Cardiol 1988;11:453-463.
26. The GUSTO Angiographic Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329: 1615-1622.
27. Mauri F, Gasparini M, Barbonglia L, Santoro E, Franzosi MG, Tognoni G, Rovelli F. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). Am J Cardiol 1989;63:1291-7.
28. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
29. Fung AY, Jue J, Henning H, Thompson CR, Davies C, Buller CE. Second infarction: Low prevalence of ST elevation and thrombolytic use. Circulation 1994;90:I-167.